Sarepta Therapeutics (SRPT) has announced that it has teamed up with Codiak BioSciences to design and develop engineered exosome therapeutics to deliver gene therapy, …
Sarepta Therapeutics (SRPT) has reported weaker-than-expected earning results for the first quarter. Specifically, Q1 Non-GAAP EPS of -$1.
There’s a new FDA-approved DMD medication on the scene. On Friday, the FDA green-lighted Sarepta Therapeutics’ (SRPT) Vyondys 53, the company’s treatment for …
Christmas is over and it seems like people spent their gift money on stocks… Sarepta Therapeutics (SRPT) stock rose over 10% is the …
Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target. The analyst noted, “The FDA’s …
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price …
In a research report issued today, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following today’s news of the termination of …
In a research note released yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics (SRPT), and a price target of $34.00.
In a research report issued yesterday, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following data release from …